AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 191 min read$XFOR

Craig Adam R purchased $12K of XFOR

Craig Adam R (Executive Chairman) purchased 4,600 shares of X4 Pharmaceuticals, Inc (XFOR) at $2.58 on 2026-10-16.

Original reporting
SEC EDGAR · Craig Adam R
Published Oct 19, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$XFOR
Neutral
high confidence
Mentioned
$XFOR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XFORNeutralLow
01

Why it matters

The filing provides a fresh, primary disclosure of a modest insider purchase, offering limited trading insight.

02

Market read

Small insider buy with minimal market impact; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Insider's overall holdings remain large; the transaction does not materially change ownership percentage.

Relevance 4/10Novelty 3/10Timing: after-hours filing today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$XFORNeutralHigh confidence
Context

Executive Chairman Craig Adam R purchased 4,600 shares of X4 Pharmaceuticals at $2.58 each, totaling $11,884.

Expected impact

minor upward pressure as market prices in the insider buy

Evidence & confidence

Form 4 filing is primary source; purchase amount is low relative to market cap, limiting impact.

Market effects

Sector

None significant for the broader biotech sector.

Regional

Limited to U.S. markets where XFOR trades.

Global

Low

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • company
    X4 Pharmaceuticals, Inc.

    Biopharmaceutical company listed on Nasdaq under ticker XFOR.

  • person
    Craig Adam R

    Executive Chairman of X4 Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

XFOR insider trading history →

Related articles

OCT 29
$XFORMed

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals (XFOR) reported blinded data from its 4WARD study, showing promising results for mavorixafor in treating chronic neutropenia. The company plans to initiate a Phase II study (4STEPS) in 2027 to evaluate G-CSF reduction. X4 estimates a 15,000-patient U.S. market opportunity, with potential expansion to 30,000 patients. Clinicians highlighted the high disease burden and need for new treatments.

finance.yahoo.com4 min
OCT 8
$XFORMedAI 8/10

X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

X4 Pharmaceuticals (XFOR) secured up to $150M in debt financing from K2 HealthVentures, refinancing existing debt and providing additional capital. The initial $80M tranche was used to repay $75M in outstanding debt. The new agreement offers extended repayment terms and supports clinical development, including the potential commercial launch of mavorixafor for chronic neutropenia.

finance.yahoo.com2 min